Agios shares crashed 49% premarket after its sickle-cell drug Mitapivat delivered mixed Phase 3 results. The treatment met its primary goal by improving haemoglobin levels, but its reduction in sickle-cell pain crises did not reach statistical significance. The study included patients aged 16 and older.